These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2132 related articles for article (PubMed ID: 28263422)

  • 21. Correlation of [
    Pisani C; Vigna L; Mastroleo F; Loi G; Amisano V; Masini L; Deantonio L; Aluffi Valletti P; Sacchetti G; Krengli M
    Radiat Oncol; 2021 Mar; 16(1):57. PubMed ID: 33743759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.
    Chen SW; Hsieh TC; Yen KY; Yang SN; Wang YC; Chien CR; Liang JA; Kao CH
    Laryngoscope; 2014 Dec; 124(12):2732-8. PubMed ID: 25042474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prognostic Significance of Tumor SUVmax Value in Pre- and Post-Chemoradiotherapy 18F-FDG PET/CT Imaging in Patients with Localized and Advanced Head and Neck Squamous Cell Carcinoma.
    Kandemir O; Demir F; Avcı GG
    Niger J Clin Pract; 2024 Jun; 27(6):748-753. PubMed ID: 38943299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
    Sagardoy T; Fernandez P; Ghafouri A; Digue L; Haaser T; de Clermont-Galleran H; Castetbon V; de Monès E
    Head Neck; 2016 Apr; 38 Suppl 1():E1271-6. PubMed ID: 26315809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Accuracy of
    Murtojärvi S; Malaspina S; Kinnunen I; Tuokkola T; Honka MJ; Saunavaara V; Tolvanen T; Schrey A; Kemppainen J
    Contrast Media Mol Imaging; 2022; 2022():8676787. PubMed ID: 36082064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings.
    Matoba M; Tuji H; Shimode Y; Kondo T; Oota K; Tonami H
    Br J Radiol; 2017 Mar; 90(1071):20150404. PubMed ID: 28055245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
    Wong KH; Panek R; Welsh L; Mcquaid D; Dunlop A; Riddell A; Murray I; Du Y; Chua S; Koh DM; Bhide S; Nutting C; Oyen WJ; Harrington K; Newbold KL
    J Nucl Med; 2016 Dec; 57(12):1843-1850. PubMed ID: 27417648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E
    Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of the
    Wakisaka R; Kumai T; Komatsuda H; Yamaki H; Kono M; Sato R; Ohara K; Kishibe K; Hayashi T; Okizaki A; Takahara M
    Clin Otolaryngol; 2024 Nov; 49(6):733-741. PubMed ID: 38950901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of subclinical recurrence or second primary cancer using (18) F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma.
    Kikuchi M; Shinohara S; Hino M; Itoh K; Tona R; Kishimoto I; Harada H; Fujiwara K; Suehiro A; Naito Y
    Head Neck; 2016 Apr; 38 Suppl 1():E511-8. PubMed ID: 25783743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
    Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
    Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 107.